Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RBP4 | P02753 | 12/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766132 | 0.85 | RBP4 (0.49) | MEN1KMT2ARBP4DRD2DRD3 | |
| SCHEMBL631348 | 0.85 | SRD5A2 (0.59) | MEN1KMT2ARBP4DRD2DRD3 | |
| SCHEMBL631387 | 0.83 | MEN1 (0.53) | MEN1KMT2ARBP4HSD17B10 | |
| SCHEMBL630813 | 0.82 | DRD2 (0.47) | MEN1KMT2ARBP4DRD2DRD3 | |
| SCHEMBL766169 | 0.81 | RBP4 (0.69) | MEN1KMT2ARBP4KDM4EALDH1A1 | |
| SCHEMBL27873706 | 0.77 | RBP4 (0.51) | MEN1KMT2ARBP4SMN1; SMN2HSD17B10 | |
| SCHEMBL766179 | 0.75 | RBP4 (0.72) | MEN1KMT2ARBP4 | |
| SCHEMBL766165 | 0.75 | RBP4 (0.51) | KMT2ARBP4ALDH1A1 | |
| SCHEMBL766303 | 0.74 | RBP4 (0.57) | RBP4GAA | |
| SCHEMBL766224 | 0.69 | RBP4 (0.62) | MEN1KMT2ARBP4ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | MEN1 3929/4885KMT2A 802/4885RBP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.